# FEATURE FDG-PET/CT response assessment

Source: https://onco.cc/trials/nct04316117/  
OnCo record `nct04316117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FEATURE studies whether PET/CT scans can measure treatment response in breast cancer that has spread mainly to bones. It evaluates imaging rather than assigning a new cancer treatment.

## Summary

FEATURE studies whether PET/CT scans can measure treatment response in breast cancer that has spread mainly to bones. It evaluates imaging rather than assigning a new cancer treatment.

Interventional study registered as NCT04316117, sponsored by ECOG-ACRIN Cancer Research Group. Registry phase: 2. Registry enrollment is 138 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT04316117
- Phase: 2
- Setting: Bone-dominant metastatic breast cancer
- Sponsor: ECOG-ACRIN Cancer Research Group
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT04316117: https://clinicaltrials.gov/study/NCT04316117
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT04316117

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct04316117.json